# Montelukast API Market

> Montelukast API Market Research Report Information By Application (Asthma, Allergic Rhinitis, Bronchospasm, Urticaria, and Others), and By Region (North America, Europe, Asia-Pacific, And Rest Of The World) –Market Forecast Till 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 10.8%
- **2024:** $ 1.01 Billion
- **2025:** $ 1.12 Billion
- **2035:** $ 3.12 Billion
- **Key Players:** Merck & Co. (US), Teva Pharmaceutical Industries Ltd. (IL), Mylan N.V. (NL), Sandoz International GmbH (CH), Aurobindo Pharma(IN), Cipla Limited (IN), Hikma Pharmaceuticals PLC (GB), Zydus Cadila (IN)

**Report ID:** MRFR/HC/6414-CR · **Pages:** 94 · **Author:** Vikita Thakur & Rahul Gotadki · **Last Updated:** May 15, 2026

**URL:** https://www.marketresearchfuture.com/reports/montelukast-api-market-7886

---

## Market Summary

## **Global Montelukast API Market Overview**

Montelukast API Market Size was valued at USD 0.9 Billion in 2023. The montelukast API market industry is projected to grow from USD 1.01 Billion in 2024 to USD 2.30 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 10.80% during the forecast period (2024 - 2032).The increase in the prevalence of disorders like asthma, exercise-induced bronchospasm, allergic rhinitis, primary dysmenorrhea, and urticaria are the key market drivers enhancing the market growth. The availability of well-established healthcare facilities and improvements in treatment alternatives are two more aspects that impact the market.

Source: Secondary Research, Primary Research, _Market Research Future_ Database and Analyst Review

## **Montelukast API Market Trends**

### **Growing prevalence of asthma is driving the market growth**

Market CAGR for montelukast API is driven by the increasing number of people who have asthma. Globally rising rates of chronic respiratory disorders like asthma are one of the major market factors driving this industry. Since asthma is estimated to be the most common chronic condition globally, there has been a significant demand for innovative treatments. If someone has severe asthma, it can be a crippling illness requiring asthma medicine. Hence, the market expansion is expected to be supported by the increased need for people with asthma to have higher-quality lifestyles.

As per the American Academy of Asthma, Allergy & Immunology, 8.3% of kids in the US were predicted to have asthma in 2016. Creating economical and effective treatments will drive market expansion during the forecast period.

Worldwide pollution levels are increasing as a result of growing industrialization. The environment's carbon content is rising due to the overuse of coal in creating electricity and other production activities, raising temperatures. On the other hand, people's purchasing power is growing due to rising disposable income. They are purchasing automobiles as a result. All of these causes contribute to increased pollution, which worsens existing health issues, including asthma and allergic coryza. According to the WHO, asthma and other bronchial issues can develop in sensitive people when the air quality is above 101.

Following this, nations like China and India have taken the lead in having high AQI, which will contribute to market expansion.

The world population is expanding steadily, particularly in Asian countries like China and India, which comprise around 36% of the population. Around 4.6 billion of the world's 7.9 billion inhabitants reside in Asia. Along with the general population increase, the elderly population is also rising. There are about 700 million individuals over the age of 65, and that figure is projected to grow to between 1 and 2 billion soon. Respiratory issues are more likely in older age, bringing physical suffering.

The strong and vigorous R&D efforts made by major industry players to produce montelukast API are one of the significant market trends currently dominating this market. Since asthma is a chronic condition affecting many people globally, including children, several renowned pharmaceutical companies are working to produce asthma medications. Several promising asthma treatment candidates undergo various clinical trial stages as part of this involvement. Thus, driving the montelukast API market revenue.

## **Montelukast API Market Segment Insights**

### **Montelukast API Application Insights**

The montelukast API market segmentation, based on application, includes asthma, allergic rhinitis, bronchospasm, urticaria, and others. The asthma segment dominated the market, accounting for 46.9% of market revenue (0.4 Billion). By preventing symptoms like wheezing, breathing issues, chest tightness, and coughing, montelukast sodium treats asthma in adults and children 12 months and older. Asthma, among the most prevalent ailments in the world, can be fatal and make breathing challenging for patients. Around 6.2 million children under the age of 18 have asthma.

Asthma is responsible for 1.8 million trips to the emergency room, 188,968 hospital inpatient discharges, and 9.8 million visits to the doctor's office annually.

**April 2020: **Cipla Limited announced the successful completion of the Phase-3 clinical end-point trial for salmeterol inhalation powder and fluticasone propionate (50/100 mcg). Salmeterol inhalation and fluticasone propionate powder 500/50 mcg, 250/50 mcg, and 100/50 mcg are the generic equivalents of GSK's Advair Diskus. The medicine, a twice-daily prescription tablet, is intended for the prolonged treatment of [chronic obstructive pulmonary disease](../../../reports/chronic-obstructive-pulmonary-disease-copd-market-1612) in patients with asthma who are at least four years and have chronic bronchitis, emphysema, or both. This will result in better breathing and fewer asthma attacks.

Additionally, in 2022, allergic rhinitis witnessed the fastest growth rate due to variables including pollen, a powder produced by many trees, grasses, and flowers that causes allergic rhinitis. Growing carbon dioxide emissions eventually contaminate the ecosystem and lengthen pollen seasons. The prolonged pollen season accelerates the occurrence of illnesses like headaches, dark undereye bags, runny nose, coughing, and throat pain.

**Figure 1: Montelukast API Market, by Application, 2022 & 2032 (USD Billion)**

_Source: Secondary Research, Primary Research, _Market Research Future_ Database and Analyst Review_

### **Montelukast API Regional Insights**

By region, the study provides market insights into North America, Europe, Asia-Pacific and Rest of the World. The Asia-Pacific Montelukast API Market area will dominate this market. This increase results from an aging population, particularly in developing nations like India and China, and an increase in pollution because these two nations are the largest emitters of carbon dioxide, making asthmatic conditions worse. On the other hand, because of their growing GDPs, these countries can afford to invest more money in R&D.

Moreover, China’s montelukast API market held the major market share, and the Indian montelukast API market was the rapidly growing market in the Asia-Pacific region.

Further, the major countries studied in the market report are US, Canada, France, German, Italy, UK, Spain, Japan, China, Australia, India, South Korea, and Brazil.

**Figure 2: ****Montelukast API Market Share By Region 2022 (USD Billion)**

_Source: Secondary Research, Primary Research, _Market Research Future_ Database and Analyst Review_

The North American Montelukast API market accounts for the second-largest market share. Its significant market share is attributable to several factors, including the existence of prominent players, the high prevalence of asthma and other respiratory disorders, and the well-established healthcare infrastructure. In addition, encouraging government initiatives and a rise in research collaboration numbers are anticipated to boost market expansion. Moreover, the U.S. montelukast API market held the major market share, and the Canadian montelukast API market was the rapidly growing market in the Asia-Pacific region.

Europe’s Montelukast API Market is expected to grow at the fastest CAGR from 2024 to 2032 because eminent academics worldwide and top pharmaceutical firms like GSK and AstraZeneca are there. The area has a strong potential for cutting-edge cures and conducts top-notch research in [bioinformatics](../../../reports/bioinformatics-market-2265) and digital technology. Further, the German montelukast API market held the largest market share, and the UK montelukast API market was the rapidly growing market in the European region.

## **Montelukast API Key Market Players & Competitive Insights**

Leading market players are largely investing in research and development to expand their product lines, which will help the montelukast API market, grow even more. The launch of new products, larger-scale mergers and acquisitions, contractual agreements, and collaboration with other organizations are significant market developments in which market participants engage to increase their presence. The Montelukast API industry must provide affordable products to expand and thrive in a more competitive and challenging market environment.

One of the major business strategies manufacturers use in the montelukast API industry to increase market sector and benefit customers is local manufacturing to lower operational costs. In recent years, the montelukast API industry has stipulated some of the most important medicinal benefits. Major players in the montelukast API industry, including Teva Pharmaceutical Industries Ltd (Israel), Sandoz International GmbH (Germany), Vintage Pharmaceuticals Inc (US), Morepen Laboratories Ltd (India), and others, are funding operations for research and development to boost market demand.

Morepen Laboratories is a renowned Pharmaceutical Company in Active Pharmaceutical Ingredients and Formulations. Morepen Laboratories Limited, founded in 1984 by Mr. KB Suri, began as a pure API manufacturer. The company manufactures and sells active formulations, pharmaceutical ingredients (APIs), and home health products. With approvals from all the major regulatory agencies, including the USFDA, WHO GMP, and EU GMP, Morepen has an important international footprint and distributes to over 75 countries. In December 2021, Morepen Laboratories announced that it had got approval from the US Food and Medicine Administration to market its anti-allergy medicine Fexofenadine Hydrochloride in the United States.

In India, the medicine is marketed under the brand Allegra.

Valeo Pharma Inc is a Canadian specialty pharmaceutical business focused on acquisitions, in-licensing, and similar partnerships. It now markets Synacthen Depot, a synthetic ACTH medication used in cases where natural cortisol and other hormone synthesis is needed. In March 2021, Valeo Pharma Inc. announced a Commercialization and Supply Contract with Novartis Pharmaceuticals Canada Inc. for the Canadian marketing of two asthma therapies, Enerzair Breezhaler (indacaterol (as acetate), glycopyrronium (as bromide), and mometasone furoate) and Atectura Breezhaler (indacaterol (as acetate) and mometasone furoate).

### **Key Companies in the Montelukast API market include**

- Sandoz International GmbH (Germany)
- [Teva Pharmaceutical](https://www.teva-api.com/products/montelukast-sodium/) Industries Ltd (Israel)
- [Dr. Reddys Laboratories](https://api.drreddys.com/product/montelukast-sodium) Ltd (India)
- Morepen Laboratories Ltd (India)
- Mylan N.V. (US)
- Vintage Pharmaceuticals Inc (US)
- Hikma Pharmaceuticals PLC (UK)
- Glenmark (India)
- Merck Sharp and Dohme Corp (US)
- Sandoz International GmbH (Germany)
- Hetero (India)
- Aurobindo Pharma (India)

## **Montelukast Api Market Industry Developments**

- **Q2 2025: Corti Raises $60 Million to Expand AI Co-Pilot for Healthcare Providers** Corti, a Copenhagen-based health tech startup, secured $60 million in funding to scale its AI-powered co-pilot platform, which assists healthcare providers with real-time triage, documentation automation, and clinical decision support, currently used in approximately 55 million medical consultations annually.
- **Q2 2024: Accenture Acquires Nautilus Consulting to Strengthen Digital Health Capabilities** Accenture announced the acquisition of UK-based Nautilus Consulting, a healthcare technology consultancy specializing in electronic patient record (EPR) solutions, to bolster its digital health and transformation services for hospitals and health systems.
- **Q1 2024: PwC Appoints New Global Health Industries Leader** PwC named Dr. Tim Wilson as its new Global Health Industries Leader, overseeing the firm's healthcare consulting strategy and client engagements across more than 50 countries.
- **Q2 2025: Deloitte Launches GenAI Consulting Practice for Healthcare Providers** Deloitte introduced a dedicated Generative AI consulting practice focused on helping healthcare organizations implement advanced AI solutions for clinical workflow optimization, patient engagement, and operational efficiency.
- **Q1 2025: McKinsey & Company Wins Major NHS Digital Transformation Contract** McKinsey & Company secured a multi-year contract with the UK National Health Service (NHS) to provide strategic consulting for the rollout of digital health platforms and interoperability solutions across regional trusts.
- **Q2 2024: KPMG Opens New Healthcare Innovation Hub in Singapore** KPMG inaugurated a Healthcare Innovation Hub in Singapore to support Asia-Pacific clients with consulting services in digital health, regulatory compliance, and operational transformation.
- **Q1 2025: EY Acquires HealthTech Advisory Firm to Expand Consulting Portfolio** EY announced the acquisition of a leading healthtech advisory firm, enhancing its healthcare consulting capabilities in digital transformation, data analytics, and regulatory strategy for hospitals and payers.
- **Q2 2025: Huron Consulting Group Appoints New Chief Executive Officer** Huron Consulting Group named Mark Hussey as its new CEO, signaling a strategic focus on expanding healthcare consulting services in digital transformation and operational improvement.
- **Q1 2024: Guidehouse Completes Acquisition of Grant Thornton’s Public Sector Healthcare Practice** Guidehouse finalized the acquisition of Grant Thornton’s public sector healthcare consulting division, strengthening its advisory services for government health agencies and public health initiatives.
- **Q2 2024: IQVIA Launches New Patient Engagement Consulting Service** IQVIA introduced a consulting service focused on patient engagement strategies, leveraging digital tools and analytics to help healthcare providers improve patient outcomes and satisfaction.
- **Q1 2025: Bain & Company Partners with Epic Systems for EHR Optimization Consulting** Bain & Company announced a strategic partnership with Epic Systems to offer joint consulting services for electronic health record (EHR) optimization and digital transformation projects for hospitals.
- **Q2 2025: ZS Associates Wins Contract to Advise on US Medicaid Modernization** ZS Associates secured a consulting contract to advise several US states on Medicaid modernization, focusing on digital infrastructure upgrades and process optimization.

## **Montelukast API Market Segmentation**

### **Montelukast API Application Outlook**

- Asthma
- Allergic Rhinitis
- Bronchospasm
- Urticaria
- Others

### **Montelukast API Regional Outlook**

## Market Drivers

### Rising Healthcare Expenditure

An increase in healthcare expenditure across various regions is a significant driver for the Montelukast API Market. As countries allocate more resources to healthcare, there is a corresponding rise in the availability and accessibility of medications for chronic conditions such as asthma and allergies. This trend is particularly evident in emerging economies, where healthcare reforms are aimed at improving patient outcomes. The Montelukast API Market, being a cost-effective treatment option, is likely to benefit from this increased spending. Furthermore, the emphasis on preventive healthcare and [chronic disease management](https://www.marketresearchfuture.com/reports/chronic-disease-management-market-981) aligns with the therapeutic profile of Montelukast, suggesting a favorable market environment for its continued growth.

### Regulatory Approvals and Guidelines

The Montelukast API Market is significantly influenced by regulatory approvals and clinical guidelines that endorse the use of Montelukast for various respiratory conditions. Regulatory bodies, such as the FDA and EMA, have established guidelines that facilitate the approval process for new formulations and generics of Montelukast. This regulatory support not only enhances market accessibility but also encourages pharmaceutical companies to invest in research and development. As a result, the market is witnessing an influx of new entrants and innovative formulations, which could potentially expand the therapeutic applications of Montelukast. The alignment of clinical guidelines with emerging research further solidifies the role of Montelukast in asthma and allergy management, thereby driving market growth.

### Increasing Prevalence of Asthma and Allergies

The rising incidence of asthma and allergic conditions is a primary driver for the Montelukast API Market. According to recent data, asthma affects approximately 300 million individuals worldwide, with a notable increase in prevalence among children. This growing patient population necessitates effective treatment options, thereby propelling the demand for Montelukast, a well-established leukotriene receptor antagonist. As healthcare providers seek to manage these chronic conditions more effectively, the Montelukast API Market is likely to experience substantial growth. Furthermore, the increasing awareness of asthma management strategies among patients and healthcare professionals contributes to the heightened demand for Montelukast, reinforcing its position in the therapeutic landscape.

### Technological Advancements in Drug Delivery Systems

Technological advancements in drug delivery systems are poised to impact the Montelukast API Market positively. Innovations such as smart inhalers and sustained-release formulations enhance the efficacy and patient compliance of Montelukast. These advancements not only improve the therapeutic outcomes for patients but also create new market opportunities for pharmaceutical companies. As the industry embraces these technologies, the Montelukast API Market is likely to be integrated into more sophisticated delivery systems, thereby expanding its market reach. The potential for personalized medicine, where treatments are tailored to individual patient needs, further underscores the importance of these technological developments in shaping the future of the Montelukast API Market.

### Growing Awareness and Education on Respiratory Health

The increasing awareness and education regarding respiratory health are crucial drivers for the Montelukast API Market. Public health campaigns and educational initiatives aimed at asthma and allergy management have led to a greater understanding of these conditions among patients and healthcare providers. This heightened awareness encourages individuals to seek treatment options, including Montelukast, thereby driving demand. Additionally, healthcare professionals are more equipped to recommend Montelukast as a viable treatment option, further enhancing its market presence. The focus on respiratory health education is likely to continue, suggesting a sustained growth trajectory for the Montelukast API Market as more patients become informed about their treatment choices.

## Future Outlook

The Montelukast API Market is projected to grow at a 10.8% CAGR from 2025 to 2035, driven by increasing asthma prevalence, rising healthcare expenditure, and advancements in drug formulation.

**New opportunities:**

- Expansion into emerging markets with tailored formulations Development of combination therapies to enhance efficacy Investment in digital health platforms for patient engagement

By 2035, the Montelukast API Market is expected to achieve substantial growth and innovation.

## Segment Insights

### By Application: Asthma (Largest) vs. Allergic Rhinitis (Fastest-Growing)

In the Montelukast API Market, the application segment is largely dominated by asthma treatment, accounting for a significant portion of the total market share. Allergic rhinitis, while smaller, has been gaining traction, driven by increasing awareness and prescription rates among healthcare providers. The other applications, including bronchospasm, urticaria, and others, contribute less to the overall shares but are essential components of the market dynamics.

Asthma (Dominant) vs. Allergic Rhinitis (Emerging)

Asthma remains the dominant application segment within the Montelukast API Market, driven by a high prevalence of the condition globally and ongoing prescription trends. On the other hand, allergic rhinitis is emerging as a significant contender due to elevated allergen exposure and enhanced public awareness regarding treatment options. The growing focus on addressing respiratory conditions alongside allergic reactions will continue to shape the market landscape, with asthma taking the lead while allergic rhinitis sees rapid growth and increased market penetration.

## Regional Market Share Analysis

### North America : Market Leader in Innovation

North America is the largest market for Montelukast API Market, holding approximately 45% of the global market share. The region benefits from advanced healthcare infrastructure, high prevalence of asthma and allergies, and strong regulatory support from agencies like the FDA. The increasing demand for effective asthma management solutions is driving growth, alongside a rise in generic drug approvals, which enhances market accessibility. The United States is the primary contributor, with significant participation from Canada. Key players such as Merck & Co. and Teva Pharmaceutical Industries dominate the landscape, leveraging their extensive distribution networks and R&D capabilities. The competitive environment is characterized by a focus on innovation and strategic partnerships, ensuring a steady supply of Montelukast API Market to meet growing healthcare needs.

### Europe : Emerging Market with Regulations

Europe is the second-largest market for Montelukast API Market, accounting for around 30% of the global share. The region's growth is propelled by increasing asthma prevalence, supportive regulatory frameworks, and a strong emphasis on generic medications. The European Medicines Agency (EMA) plays a crucial role in facilitating market entry for new generics, which enhances competition and affordability for patients. Leading countries include Germany, France, and the UK, where the presence of major pharmaceutical companies like Mylan N.V. and Sandoz International GmbH strengthens the market. The competitive landscape is marked by a mix of established players and emerging firms, all striving to capture market share through innovation and cost-effective solutions. The focus on patient-centric approaches further drives demand for Montelukast API Market in the region.

### Asia-Pacific : Rapid Growth and Demand

Asia-Pacific is witnessing rapid growth in the Montelukast API Market, holding approximately 20% of the global share. The region's expansion is driven by increasing healthcare expenditure, rising awareness of asthma management, and a growing population. Countries like India and China are at the forefront, with supportive government initiatives aimed at enhancing healthcare access and affordability, which are crucial for market growth. India is a significant player, with companies like Aurobindo Pharma and Cipla Limited leading the charge in production and distribution. The competitive landscape is evolving, with both local and international firms vying for market share. The focus on cost-effective solutions and the increasing demand for generics are shaping the market dynamics, making Asia-Pacific a key region for Montelukast API Market.

### Middle East and Africa : Untapped Potential in Healthcare

The Middle East and Africa (MEA) region is gradually emerging in the Montelukast API Market, currently holding about 5% of the global share. The growth is driven by increasing healthcare investments, rising awareness of respiratory diseases, and a growing population. Regulatory bodies are beginning to implement frameworks that support the introduction of generic medications, which is expected to enhance market accessibility in the coming years. Countries like South Africa and the UAE are leading the way, with a growing number of local manufacturers entering the market. The competitive landscape is characterized by a mix of multinational corporations and regional players, all aiming to meet the rising demand for effective asthma treatments. The focus on improving healthcare infrastructure and patient access is crucial for the region's growth in the Montelukast API Market.

## Competitive Benchmarking

Leading market players are largely investing in research and development to expand their product lines, which will help the montelukast API market, grow even more. The launch of new products, larger-scale mergers and acquisitions, contractual agreements, and collaboration with other organizations are significant market developments in which market participants engage to increase their presence. The Montelukast API industry must provide affordable products to expand and thrive in a more competitive and challenging market environment.
One of the major business strategies manufacturers use in the montelukast API industry to increase market sector and benefit customers is local manufacturing to lower operational costs. In recent years, the montelukast API industry has stipulated some of the most important medicinal benefits. Major players in the montelukast API industry, including Teva Pharmaceutical Industries Ltd (Israel), Sandoz International GmbH (Germany), Vintage Pharmaceuticals Inc (US), Morepen Laboratories Ltd (India), and others, are funding operations for research and development to boost market demand.
Morepen Laboratories is a renowned Pharmaceutical Company in Active Pharmaceutical Ingredients and Formulations. Morepen Laboratories Limited, founded in 1984 by Mr. KB Suri, began as a pure API manufacturer. The company manufactures and sells active formulations, pharmaceutical ingredients (APIs), and home health products. With approvals from all the major regulatory agencies, including the USFDA, WHO GMP, and EU GMP, Morepen has an important international footprint and distributes to over 75 countries.
In December Morepen Laboratories announced that it had got approval from the US Food and Medicine Administration to market its anti-allergy medicine Fexofenadine Hydrochloride in the United States.
In India, the medicine is marketed under the brand Allegra.
Valeo Pharma Inc is a Canadian specialty pharmaceutical business focused on acquisitions, in-licensing, and similar partnerships. It now markets Synacthen Depot, a synthetic ACTH medication used in cases where natural cortisol and other hormone synthesis is needed.
In March Valeo Pharma Inc. announced a Commercialization and Supply Contract with Novartis Pharmaceuticals Canada Inc. for the Canadian marketing of two asthma therapies, Enerzair Breezhaler (indacaterol (as acetate), glycopyrronium (as bromide), and mometasone furoate) and Atectura Breezhaler (indacaterol (as acetate) and mometasone furoate).

## Recent News & Developments

- **Q2 2025: Corti Raises $60 Million to Expand AI Co-Pilot for Healthcare Providers** Corti, a Copenhagen-based health tech startup, secured $60 million in funding to scale its AI-powered co-pilot platform, which assists healthcare providers with real-time triage, documentation automation, and clinical decision support, currently used in approximately 55 million medical consultations annually.
- **Q2 2024: Accenture Acquires Nautilus Consulting to Strengthen Digital Health Capabilities** Accenture announced the acquisition of UK-based Nautilus Consulting, a healthcare technology consultancy specializing in electronic patient record (EPR) solutions, to bolster its digital health and transformation services for hospitals and health systems.
- **Q1 2024: PwC Appoints New Global Health Industries Leader** PwC named Dr. Tim Wilson as its new Global Health Industries Leader, overseeing the firm's healthcare consulting strategy and client engagements across more than 50 countries.
- **Q2 2025: Deloitte Launches GenAI Consulting Practice for Healthcare Providers** Deloitte introduced a dedicated Generative AI consulting practice focused on helping healthcare organizations implement advanced AI solutions for clinical workflow optimization, patient engagement, and operational efficiency.
- **Q1 2025: McKinsey & Company Wins Major NHS Digital Transformation Contract** McKinsey & Company secured a multi-year contract with the UK National Health Service (NHS) to provide strategic consulting for the rollout of digital health platforms and interoperability solutions across regional trusts.
- **Q2 2024: KPMG Opens New Healthcare Innovation Hub in Singapore** KPMG inaugurated a Healthcare Innovation Hub in Singapore to support Asia-Pacific clients with consulting services in digital health, regulatory compliance, and operational transformation.
- **Q1 2025: EY Acquires HealthTech Advisory Firm to Expand Consulting Portfolio** EY announced the acquisition of a leading healthtech advisory firm, enhancing its healthcare consulting capabilities in digital transformation, data analytics, and regulatory strategy for hospitals and payers.
- **Q2 2025: Huron Consulting Group Appoints New Chief Executive Officer** Huron Consulting Group named Mark Hussey as its new CEO, signaling a strategic focus on expanding healthcare consulting services in digital transformation and operational improvement.
- **Q1 2024: Guidehouse Completes Acquisition of Grant Thornton’s Public Sector Healthcare Practice** Guidehouse finalized the acquisition of Grant Thornton’s public sector healthcare consulting division, strengthening its advisory services for government health agencies and public health initiatives.
- **Q2 2024: IQVIA Launches New Patient Engagement Consulting Service** IQVIA introduced a consulting service focused on patient engagement strategies, leveraging digital tools and analytics to help healthcare providers improve patient outcomes and satisfaction.
- **Q1 2025: Bain & Company Partners with Epic Systems for EHR Optimization Consulting** Bain & Company announced a strategic partnership with Epic Systems to offer joint consulting services for electronic health record (EHR) optimization and digital transformation projects for hospitals.
- **Q2 2025: ZS Associates Wins Contract to Advise on US Medicaid Modernization** ZS Associates secured a consulting contract to advise several US states on Medicaid modernization, focusing on digital infrastructure upgrades and process optimization.

## Report Scope

| MARKET SIZE 2024 | 1.01(USD Billion) |
| --- | --- |
| MARKET SIZE 2025 | 1.119(USD Billion) |
| MARKET SIZE 2035 | 3.121(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 10.8% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | Merck & Co. (US), Teva Pharmaceutical Industries Ltd. (IL), Mylan N.V. (NL), Sandoz International GmbH (CH), Aurobindo Pharma (IN), Cipla Limited (IN), Hikma Pharmaceuticals PLC (GB), Zydus Cadila (IN) |
| Segments Covered | Application, Region |
| Key Market Opportunities | Emerging regulatory frameworks may enhance growth prospects in the Montelukast API Market. |
| Key Market Dynamics | Rising demand for Montelukast API driven by regulatory shifts and increasing prevalence of respiratory disorders. |
| Countries Covered | North America, Europe, APAC, South America, MEA |

## Frequently Asked Questions

**Q: What is the current valuation of the Montelukast API Market as of 2024?**
A: The Montelukast API Market was valued at 1.01 USD Billion in 2024.

**Q: What is the projected market valuation for the Montelukast API Market in 2035?**
A: The market is projected to reach a valuation of 3.121 USD Billion by 2035.

**Q: What is the expected CAGR for the Montelukast API Market during the forecast period 2025 - 2035?**
A: The expected CAGR for the Montelukast API Market during 2025 - 2035 is 10.8%.

**Q: Which companies are considered key players in the Montelukast API Market?**
A: Key players in the market include Merck & Co., Teva Pharmaceutical Industries Ltd., Mylan N.V., Sandoz International GmbH, Aurobindo Pharma, Cipla Limited, Hikma Pharmaceuticals PLC, and Zydus Cadila.

**Q: What application segment had the highest valuation in the Montelukast API Market in 2024?**
A: In 2024, the Asthma application segment had the highest valuation at 0.404 USD Billion.

**Q: How does the valuation of the Allergic Rhinitis segment compare to the Bronchospasm segment in 2024?**
A: In 2024, the Allergic Rhinitis segment was valued at 0.303 USD Billion, while the Bronchospasm segment was valued at 0.202 USD Billion.

**Q: What is the projected growth for the Urticaria segment in the Montelukast API Market by 2035?**
A: The Urticaria segment is expected to grow from 0.101 USD Billion in 2024 to 0.303 USD Billion by 2035.

**Q: What does the term 'Others' signify in the context of the Montelukast API Market segments?**
A: The 'Others' segment in the Montelukast API Market indicates a minor valuation of 0.0 USD Billion in 2024, projected to increase to 0.071 USD Billion by 2035.

**Q: How does the market performance of Montelukast API in 2024 inform future trends?**
A: The market performance in 2024, with a valuation of 1.01 USD Billion, suggests a robust growth trajectory leading to 3.121 USD Billion by 2035.

**Q: What factors might influence the growth of the Montelukast API Market in the coming years?**
A: Factors influencing growth may include advancements in asthma and allergy treatments, alongside the strategic initiatives of key players like Merck & Co. and Teva Pharmaceutical Industries.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/montelukast-api-market-7886*